Literature DB >> 16820608

High-dose atorvastatin improves hypercholesterolemic coronary endothelial dysfunction without improving the angiogenic response.

Munir Boodhwani1, Yasunari Nakai, Pierre Voisine, Jun Feng, Jian Li, Shigetoshi Mieno, Basel Ramlawi, Cesario Bianchi, Roger Laham, Frank W Sellke.   

Abstract

BACKGROUND: Although 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) can restore endothelial function in coronary disease, in vitro and murine studies have shown their effects on myocardial angiogenesis to be biphasic and dose dependent. We investigated the functional and molecular effects of high-dose atorvastatin on the endogenous angiogenic response to chronic myocardial ischemia in hypercholesterolemic swine. METHODS AND
RESULTS: Yucatan pigs were fed either a normal (NORM group; n=7) or high-cholesterol diet, with (CHOL-ATR group; n=7) or without (CHOL group; n=6) atorvastatin (3 mg/kg per day) for 13 weeks. Chronic ischemia was induced by ameroid constrictor placement around the circumflex artery. Seven weeks later, microvessel relaxation responses, myocardial perfusion, and myocardial protein expression were assessed. The CHOL group demonstrated impaired microvessel relaxation to adenosine diphosphate (29+/-3% versus 61+/-6%, CHOL versus NORM; P<0.05), which was normalized in the CHOL-ATR group (67+/-2%; P=NS versus NORM). Collateral-dependent myocardial perfusion, adjusted for baseline, was significantly reduced in the CHOL group (-0.27+/-0.07 mL/min per gram versus NORM; P<0.001) as well as the CHOL-ATR group (-0.35+/-0.07 mL/min per gram versus NORM; P<0.001). Atorvastatin treatment was associated with increased phosphorylation of Akt (5.7-fold increase versus NORM; P=0.001), decreased vascular endothelial growth factor expression (-68+/-8%; P<0.001 versus NORM), and increased expression of the antiangiogenic protein endostatin (210+/-48%; P=0.004 versus NORM).
CONCLUSIONS: Atorvastatin improves hypercholesterolemia-induced endothelial dysfunction without appreciable changes in collateral-dependent perfusion. Increased myocardial expression of endostatin, decreased expression of vascular endothelial growth factor, and chronic Akt activation associated with atorvastatin treatment may account for the diminished angiogenic response.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16820608     DOI: 10.1161/CIRCULATIONAHA.105.000356

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  18 in total

1.  Simvastatin preserves diastolic function in experimental hypercholesterolemia independently of its lipid lowering effect.

Authors:  Dallit Mannheim; Joerg Herrmann; Piero O Bonetti; Ronit Lavi; Lilach O Lerman; Amir Lerman
Journal:  Atherosclerosis       Date:  2011-02-24       Impact factor: 5.162

2.  Atorvastatin increases oxidative stress and modulates angiogenesis in Ossabaw swine with the metabolic syndrome.

Authors:  Nassrene Y Elmadhun; Antonio D Lassaletta; Louis M Chu; Yuhong Liu; Jun Feng; Frank W Sellke
Journal:  J Thorac Cardiovasc Surg       Date:  2012-09-17       Impact factor: 5.209

Review 3.  Myocardial therapeutic angiogenesis: a review of the state of development and future obstacles.

Authors:  Michael P Robich; Louis M Chu; Shizu Oyamada; Neel R Sodha; Frank W Sellke
Journal:  Expert Rev Cardiovasc Ther       Date:  2011-11

4.  Statin and resveratrol in combination induces cardioprotection against myocardial infarction in hypercholesterolemic rat.

Authors:  Suresh Varma Penumathsa; Mahesh Thirunavukkarasu; Srikanth Koneru; Bela Juhasz; Lijun Zhan; Rima Pant; Venugopal P Menon; Hajime Otani; Nilanjana Maulik
Journal:  J Mol Cell Cardiol       Date:  2006-12-26       Impact factor: 5.000

5.  Endothelium-dependent coronary vasodilatation requires NADPH oxidase-derived reactive oxygen species.

Authors:  Jun Feng; Scott M Damrauer; Monica Lee; Frank W Sellke; Christiane Ferran; Md Ruhul Abid
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-08-11       Impact factor: 8.311

6.  Impact of chronic anticholesterol therapy on development of microvascular rarefaction in the metabolic syndrome.

Authors:  Adam G Goodwill; Stephanie J Frisbee; Phoebe A Stapleton; Milinda E James; Jefferson C Frisbee
Journal:  Microcirculation       Date:  2009-11       Impact factor: 2.628

Review 7.  Pharmacotherapy for end-stage coronary artery disease.

Authors:  Neel R Sodha; Louis M Chu; Munir Boodhwani; Frank W Sellke
Journal:  Expert Opin Pharmacother       Date:  2010-02       Impact factor: 3.889

8.  Comparison of vascular endothelial growth factor and fibroblast growth factor-2 in a swine model of endothelial dysfunction.

Authors:  Munir Boodhwani; Pierre Voisine; Marc Ruel; Neel R Sodha; Jun Feng; Shu-Hua Xu; Cesario Bianchi; Frank W Sellke
Journal:  Eur J Cardiothorac Surg       Date:  2008-01-16       Impact factor: 4.191

Review 9.  Therapeutic angiogenesis in diabetes and hypercholesterolemia: influence of oxidative stress.

Authors:  Munir Boodhwani; Frank W Sellke
Journal:  Antioxid Redox Signal       Date:  2009-08       Impact factor: 8.401

10.  Atorvastatin increases myocardial indices of oxidative stress in a porcine model of hypercholesterolemia and chronic ischemia.

Authors:  Neel R Sodha; Munir Boodhwani; Basel Ramlawi; Richard T Clements; Shigetoshi Mieno; Jun Feng; Shu-Hua Xu; Cesario Bianchi; Frank W Sellke
Journal:  J Card Surg       Date:  2008 Jul-Aug       Impact factor: 1.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.